Qsep Ultra will make its first debut in Pittcon 2023

BiOptic Inc. will attend Pittcon 2023 in Pennsylvania Convention Center from March 20^th to 22^nd, presenting the unique Qsep Series products with the “Open Platform” concept, which is the best solution for overall genetic analysis. Not only the original Qsep Sereis Bio-Fragment Analyzer, and also the brand new 2 in 1 “Qsep Ultra” showing up the first time in the US market. In addition, Qsep Series products have been registered and listed in the FDA starting from this year, BiOptic may actively expand the US market and increase the market share.

Pittcon is one of the biggest laboratory instrument and technology exhibition with a long history in the United States. In the past, it attracted nearly 13,000 professionals in the related fields from around 90 countries in the globe, being the best approach for all to enter US market. It is expected to be the most important biotech tradeshow after the COVID pandemic.

The CEO of BiOptic, Eric Tsai has pointed out the brand new Qsep Ultra is combined with PCR and capillary electrophoresis techniques in one instrument. It perfectly simplifies the molecular detection workflow, and reduce the original 3-step into 2. All you need to do is sample preparation, and then put it into the fully automated Qsep Ultra. The high-resolution advantage of capillary electrophoresis can complete multiple targets gene detection in one reaction and output all the related reports. Qsep Ultra provides an innovative pathogen detection system, which fully meets the needs with the features of high accuracy, east-to-use and time saving in companion diagnosis and POCT on-site detection.

According to Allied Market Research, an international market research organization, the global genetic testing market will reach US$21.26 billion in 2027, with a compound annual growth rate of 10.1% from 2020 to 2027. CEO Eric Tsai said that the United States is the world's largest market for molecular diagnosis and genetic testing. Our core products, Qsep series is successfully registered and listed in the US FDA at the beginning of this year. This exhibition will be an opportunity to accelerate its entry into the US market. In addition, maintaining the relationship with our partners and clients in the US are also important. We will also develop new customers and partners at the same time and strive to seize market opportunities.

The market demand for biotech research and genetic testing remains high. BiOptic’s  accumulated consolidated revenue in the first two months was 19.36 million, with an increase of 9.35% year-on-year. With the growth of orders, and the emergence of the benefits of the launch of new Qsep series products, we are optimistic about the annual operating performance.